These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 28617077)

  • 1. Factors affecting immune responses to the influenza vaccine.
    Castrucci MR
    Hum Vaccin Immunother; 2018 Mar; 14(3):637-646. PubMed ID: 28617077
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunogenicity and safety of a split-virion quadrivalent influenza vaccine in adults 18-60 years of age in the Republic of Korea.
    Choi WS; Noh JY; Lee J; Choi JY; Lee JS; Kim MS; Kim HS; Bang J; Lavis N; Kim WJ
    Hum Vaccin Immunother; 2018 Mar; 14(3):587-592. PubMed ID: 28933625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Universal influenza vaccines, science fiction or soon reality?
    de Vries RD; Altenburg AF; Rimmelzwaan GF
    Expert Rev Vaccines; 2015; 14(10):1299-301. PubMed ID: 26104835
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The use of cell-mediated immunity for the evaluation of influenza vaccines: an upcoming necessity.
    Gianchecchi E; Torelli A; Montomoli E
    Hum Vaccin Immunother; 2019; 15(5):1021-1030. PubMed ID: 30614754
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial.
    van Doorn E; Pleguezuelos O; Liu H; Fernandez A; Bannister R; Stoloff G; Oftung F; Norley S; Huckriede A; Frijlink HW; Hak E
    BMC Infect Dis; 2017 Apr; 17(1):241. PubMed ID: 28376743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity and impact on disease activity of influenza and pneumococcal vaccines in systemic lupus erythematosus: a systematic literature review and meta-analysis.
    Pugès M; Biscay P; Barnetche T; Truchetet MÉ; Richez C; Seneschal J; Gensous N; Lazaro E; Duffau P
    Rheumatology (Oxford); 2016 Sep; 55(9):1664-72. PubMed ID: 27160278
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pre-vaccination immunity and immune responses to a cell culture-derived whole-virus H1N1 vaccine are similar to a seasonal influenza vaccine.
    Ehrlich HJ; Müller M; Kollaritsch H; Pinl F; Schmitt B; Zeitlinger M; Loew-Baselli A; Kreil TR; Kistner O; Portsmouth D; Fritsch S; Maritsch F; Aichinger G; Pavlova BG; Barrett PN
    Vaccine; 2012 Jun; 30(30):4543-51. PubMed ID: 22475864
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The human antibody response to influenza A virus infection and vaccination.
    Krammer F
    Nat Rev Immunol; 2019 Jun; 19(6):383-397. PubMed ID: 30837674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity and safety of the 2015 Southern Hemisphere formulation of a split-virion inactivated quadrivalent vaccine.
    Montalban C; Montellano MB; Santos J; Lavis N
    Hum Vaccin Immunother; 2018 Mar; 14(3):593-595. PubMed ID: 28933626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity, safety and tolerability of intradermal influenza vaccines.
    Hung IFN; Yuen KY
    Hum Vaccin Immunother; 2018 Mar; 14(3):565-570. PubMed ID: 28604266
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants.
    Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM
    J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A systematic review and meta-analysis of cross-reactivity of antibodies induced by oil-in-water emulsion adjuvanted influenza H5N1 virus monovalent vaccines.
    Chada KE; Forshee R; Golding H; Anderson S; Yang H
    Vaccine; 2017 May; 35(24):3162-3170. PubMed ID: 28483200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downfall of the current antibody correlates of influenza vaccine response in yearly vaccinated subjects: Toward qualitative rather than quantitative assays.
    Cagigi A; Cotugno N; Rinaldi S; Santilli V; Rossi P; Palma P
    Pediatr Allergy Immunol; 2016 Feb; 27(1):22-7. PubMed ID: 26480951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heads, stalks and everything else: how can antibodies eradicate influenza as a human disease?
    Neu KE; Henry Dunand CJ; Wilson PC
    Curr Opin Immunol; 2016 Oct; 42():48-55. PubMed ID: 27268395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influenza immunization elicits antibodies specific for an egg-adapted vaccine strain.
    Raymond DD; Stewart SM; Lee J; Ferdman J; Bajic G; Do KT; Ernandes MJ; Suphaphiphat P; Settembre EC; Dormitzer PR; Del Giudice G; Finco O; Kang TH; Ippolito GC; Georgiou G; Kepler TB; Haynes BF; Moody MA; Liao HX; Schmidt AG; Harrison SC
    Nat Med; 2016 Dec; 22(12):1465-1469. PubMed ID: 27820604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 1, open-label, randomized study to compare the immunogenicity and safety of different administration routes and doses of virosomal influenza vaccine in elderly.
    Levin Y; Kochba E; Shukarev G; Rusch S; Herrera-Taracena G; van Damme P
    Vaccine; 2016 Oct; 34(44):5262-5272. PubMed ID: 27667332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Key points in evaluating immunogenicity of pandemic influenza vaccines: A lesson from immunogenicity studies of influenza A(H1N1)pdm09 vaccine.
    Ohfuji S; Kobayashi M; Ide Y; Egawa Y; Saito T; Kondo K; Ito K; Kase T; Maeda A; Fukushima W; Hirota Y
    Vaccine; 2017 Sep; 35(39):5303-5308. PubMed ID: 28784284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Broadly protective immunity against divergent influenza viruses by oral co-administration of Lactococcus lactis expressing nucleoprotein adjuvanted with cholera toxin B subunit in mice.
    Lei H; Peng X; Jiao H; Zhao D; Ouyang J
    Microb Cell Fact; 2015 Aug; 14():111. PubMed ID: 26242406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, immunogenicity and infectivity of new live attenuated influenza vaccines.
    Isakova-Sivak I; Rudenko L
    Expert Rev Vaccines; 2015; 14(10):1313-29. PubMed ID: 26289975
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus.
    Khurana S; Chearwae W; Castellino F; Manischewitz J; King LR; Honorkiewicz A; Rock MT; Edwards KM; Del Giudice G; Rappuoli R; Golding H
    Sci Transl Med; 2010 Jan; 2(15):15ra5. PubMed ID: 20371470
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.